BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/2/2024 8:41:39 AM | Browse: 69 | Download: 253
 |
Received |
|
2024-05-07 12:18 |
|
Peer-Review Started |
|
2024-05-07 12:18 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-05-28 10:23 |
|
Revised |
|
2024-06-09 09:42 |
|
Second Decision |
|
2024-06-18 02:43 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2024-06-18 08:22 |
|
Articles in Press |
|
2024-06-18 08:22 |
|
Publication Fee Transferred |
|
2024-06-21 05:24 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-06-28 13:52 |
|
Publish the Manuscript Online |
|
2024-07-02 08:41 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Retrospective Study |
| Article Title |
Dapagliflozin and sacubitril on myocardial microperfusion in patients with post-acute myocardial infarction heart failure and type 2 diabetes
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yuan Lv and Wei-Jun Luo |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Wei-Jun Luo, BMed, Associate Chief Physician, Department of Cardiology, Lishui People's Hospital, No. 15 Mass Street, Liandu District, Lishui 323000, Zhejiang Province, China. lwj18957091539@163.com |
| Key Words |
Dagelin; Nocinto; Acute myocardial infarction; Type 2 diabetes; Heart failure; Myocardial microperfusion |
| Core Tip |
This study explored the efficacy of combining dapagliflozin and sakubactrovalsartan (noxinto) in improving myocardial microperfusion and reducing major adverse cardiovascular event incidence in patients with post–acute myocardial infarction (AMI) heart failure and type 2 diabetes mellitus (T2DM). Results indicated that compared with the control group, significant improvements in myocardial perfusion, blood glucose levels, and cardiac function along with reductions in N-terminal pro-atrial natriuretic peptide, growth differentiation factor-15, and high-sensitivity C-reactive protein levels were noted in the observation group. These findings revealed that this combination therapy may offer a novel approach for managing complex cases of post-AMI heart failure and T2DM, highlighting its potential benefits and mechanisms of action. |
| Publish Date |
2024-07-02 08:41 |
| Citation |
<p>Lv Y, Luo WJ. Dapagliflozin and sacubitril on myocardial microperfusion in patients with post-acute myocardial infarction heart failure and type 2 diabetes. <i>World J Clin Cases</i> 2024; 12(22): 5008-5015</p> |
| URL |
https://www.wjgnet.com/2307-8960/full/v12/i22/5008.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v12.i22.5008 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
